Form 8-K - Current report:
SEC Accession No. 0000950170-25-069156
Filing Date
2025-05-12
Accepted
2025-05-12 16:05:15
Documents
13
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K annx-20250512.htm   iXBRL 8-K 65398
2 EX-99.1 annx-ex99_1.htm EX-99.1 175009
3 GRAPHIC img193911374_0.jpg GRAPHIC 14203
  Complete submission text file 0000950170-25-069156.txt   394099

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT annx-20250512.xsd EX-101.SCH 28076
15 EXTRACTED XBRL INSTANCE DOCUMENT annx-20250512_htm.xml XML 4888
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 25934688
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)